Seeking Alpha

Celgene (CELG +1.4% to $86.92) is the subject of lots of analyst buzz after the company gave a...

Celgene (CELG +1.4% to $86.92) is the subject of lots of analyst buzz after the company gave a positive forecast yesterday. Jefferies raises its price target to $104 from $94 while Stifel Nicolaus ups its goal to $98 from $89, with both firms maintaining Buy ratings. RBC upgrades Celgene to Outperform from Sector Perform and ups its target to $100 from $90, while Piper Jaffray upgrades the biotech to Overweight from Neutral.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs